# Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003

> **NCT04970914** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 32 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Anlotinib
- **DRUG:** Penpulimab

## Key facts

- **NCT ID:** NCT04970914
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-05
- **Primary completion:** 2022-08-23
- **Final completion:** 2023-08-23
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2022-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04970914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04970914, "Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04970914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*